Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates

Core Viewpoint - Bristol Myers Squibb reported quarterly earnings of $1.46 per share, exceeding the Zacks Consensus Estimate of $1.07 per share, but down from $2.07 per share a year ago, indicating a significant earnings surprise of +36.45% [1][2] Financial Performance - The company achieved revenues of $12.27 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.67% and showing a slight increase from $12.2 billion in the same quarter last year [2] - Over the last four quarters, Bristol Myers has consistently exceeded consensus EPS estimates and revenue expectations [2] Stock Performance and Outlook - Bristol Myers shares have declined approximately 18.7% year-to-date, contrasting with the S&P 500's gain of 8.2% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $1.67 for the upcoming quarter and $6.28 for the current fiscal year [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, which may negatively impact stock performance [8] - The correlation between near-term stock movements and earnings estimate revisions is significant, suggesting that tracking these revisions can provide insights into stock performance [5]